683 Capital Management’s Forte Biosciences FBRX Stock Holding History

683 Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$518K	Sell	20,000 -20,000	-50%	-$576K	0.03%	181
2025 Q4	$1.09M	Buy	+40,000	New	+$701K	0.05%	131
2021 Q1	–	Sell	-1,825	Closed	-$1.66M	–	198
2020 Q4	$1.66M	Buy	+1,825	New	+$1.72M	0.08%	105
2019 Q3	–	Sell	-1,000	Closed	-$2.5M	–	157
2019 Q2	$2.5M	Hold	1,000	–	–	0.23%	76
2019 Q1	$4.08M	Hold	1,000	–	–	0.37%	56
2018 Q4	$3.08M	Buy	1,000 +867	+652%	+$3.73M	0.19%	75
2018 Q3	$780K	Hold	133	–	–	0.05%	103
2018 Q2	$467K	Buy	+133	New	+$487K	0.03%	112

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

683 Capital Management's FBRX Position: Q1 2026 in Review

683 Capital Management reduced its Forte Biosciences (FBRX) stake by 50% in Q1 2026, selling an estimated $576K and leaving 20,000 shares worth $518K. The position accounts for 0.03% of the portfolio, ranked #181.

683 Capital Management first reported a position in FBRX in Q2 2018 and has held it in 8 quarters since. The position peaked at $4.08M in Q1 2019. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

683 Capital Management held 20,000 shares of Forte Biosciences worth $518K as of Q1 2026.
683 Capital Management sold 20,000 Forte Biosciences shares in Q1 2026, an estimated $576K.
Forte Biosciences made up 0.03% of 683 Capital Management's portfolio in Q1 2026, its #181 holding.
683 Capital Management first reported a position in Forte Biosciences in Q2 2018 and has held it in 8 quarters since.
683 Capital Management's Forte Biosciences position peaked at $4.08M in Q1 2019.
68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.